Compare ETON & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETON | SPTX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2018 | 2026 |
| Metric | ETON | SPTX |
|---|---|---|
| Price | $62.53 | $26.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $39.33 | N/A |
| AVG Volume (30 Days) | ★ 626.9K | 107.2K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $79,950,000.00 | N/A |
| Revenue This Year | $40.90 | N/A |
| Revenue Next Year | $47.23 | N/A |
| P/E Ratio | $152.73 | ★ N/A |
| Revenue Growth | ★ 104.94 | N/A |
| 52 Week Low | $14.27 | $17.59 |
| 52 Week High | $66.37 | $28.37 |
| Indicator | ETON | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 70.36 | 77.83 |
| Support Level | $15.66 | $18.72 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 3.41 | 1.68 |
| MACD | 0.75 | 0.34 |
| Stochastic Oscillator | 86.65 | 96.68 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.